Biotech execs vie for a share of obesity drug boom: ‘It’s the early innings’

The GLP-1 agonist Wegovy has re-energized the hunt for obesity treatments. Alternatives — ranging from bitter taste compounds to lean muscle boosters and bacteria — are already in the clinic.